塞利尼索(Selinexor) - 药物靶点：ACADS x XPO1_在研适应症：滤泡性淋巴瘤，难治性多发性骨髓瘤，复发性多发性骨髓瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

CRM1-nuclear-export-inhibitor、NEXPOVIO、Selinexor

+ [13]

靶点

ACADS x XPO1

作用方式

抑制剂

作用机制

ACADS inhibitors(acyl-CoA dehydrogenase short chain inhibitors)、XPO1抑制剂(输出蛋白1抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [9]

在研适应症

滤泡性淋巴瘤难治性多发性骨髓瘤复发性多发性骨髓瘤+ [68]

非在研适应症

伴有 FLT3/ITD 突变的急性髓系白血病急性早幼粒细胞白血病前列腺腺癌+ [67]

原研机构

Karyopharm Therapeutics, Inc.

在研机构

德琪医药有限公司

Barbara Ann Karmanos Cancer Institute

National Cancer Institute

+ [13]

非在研机构

The University of Texas MD Anderson Cancer Center

Takeda Pharmaceutical Co., Ltd.

Millennium Pharmaceuticals, Inc.

+ [1]

权益机构

FORUSTherapeutics, Inc.

德琪（浙江）医药科技有限公司

Foundation Medicine, Inc.

+ [12]

最高研发阶段批准上市

首次获批日期

美国 (2019-07-03),

多发性骨髓瘤

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、附条件批准 (中国)、孤儿药 (韩国)、孤儿药 (澳大利亚)、优先审评 (韩国)、优先审评 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C17H11F6N7O

InChIKeyDEVSOMFAQLZNKR-RJRFIUFISA-N

CAS号1393477-72-9

关联

230

项与塞利尼索相关的临床试验

NCT07632170

/ Not yet recruitingN/AIIT

The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations: A Multicenter, Single-arm, Prospective Study

Patients with high-risk myeloid tumors accompanied by TP53 mutations have a poor survival prognosis, and there are still many unmet treatment needs. The current treatment regimens have many limitations. Selinisol, as a novel export protein inhibitor, has good anti-tumor activity. The current preclinical and preliminary clinical research results abroad suggest its effectiveness and safety. This study aims to evaluate the efficacy and safety of AZA combined with selinisole (with or without venetoclax) in the treatment of patients with high-risk myeloid tumors with TP53 mutations through a multicenter, prospective clinical study.

开始日期2026-11-01

申办/合作机构

北京协和医院

NCT07626021

/ Not yet recruiting临床2期IIT

An Open-Label, Single-Arm Phase II Study of Selinexor Monotherapy for Cytoreduction in Patients With BCR::ABL1-Negative Myeloproliferative Neoplasms

Myeloproliferative neoplasms are chronic blood cancers in which the bone marrow produces too many blood cells. Patients with Philadelphia chromosome-negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may need treatment to reduce high blood cell counts, relieve disease-related symptoms, and lower the risk of complications. However, currently available cytoreductive treatments may be ineffective, poorly tolerated, or inconvenient for some patients.
Selinexor is an oral selective inhibitor of nuclear export that has shown antitumor activity in several hematologic malignancies. This study will evaluate the effectiveness and safety of selinexor used alone as cytoreductive treatment in patients with Philadelphia chromosome-negative myeloproliferative neoplasms who have an indication for cytoreductive therapy.
This is a prospective, single-arm, open-label phase II study conducted at a single center. Eligible participants will receive oral selinexor, with dose adjustments based on tolerability and blood cell counts. Participants will be followed for treatment response, symptom improvement, and side effects for up to 6 months. The results of this study may help determine whether selinexor could provide a potential treatment option for patients with Philadelphia chromosome-negative myeloproliferative neoplasms who have limited cytoreductive therapy choices.

开始日期2026-07-01

申办/合作机构

厦门大学附属中山医院（厦门中山医院、厦门市老年病康复研究所、厦门市消化疾病研究所、厦门市临床检验中心）

NCT07479979

/ Recruiting临床1/2期IIT

Phase Ib/II Study of Selinexor in Combination With Carfilzomib, Subcutaneous Isatuximab Administered Via Investigational Device and Dexamethasone (SCID) for Patients With Relapsed and/or Relapsed Refractory Multiple Myeloma

The primary objective of this Phase Ib/II trial is to study the safety and tolerability of the combination of selinexor, carfilzomib, isatuximab-OBDS (on body delivery system) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma, who have received at least one line of therapy. The phase Ib portion comprises the safety run-in with 6-12 patients, with the option to reduce the selinexor dose from 40 mg to 20 mg if the higher dose reaches the prescribed toxicity threshold. The Phase II portion of the trial will test the Recommended Phase 2 Dose (RP2D) in an expansion cohort of up to 50 patients.

开始日期2026-07-01

申办/合作机构

Hoosier Cancer Research Network

[+3]

100 项与塞利尼索相关的临床结果

登录后查看更多信息

100 项与塞利尼索相关的转化医学

登录后查看更多信息

100 项与塞利尼索相关的专利（医药）

登录后查看更多信息

729

项与塞利尼索相关的文献（医药）

2026-12-31·ANNALS OF MEDICINE

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis

Review

作者: Li, Yuxin ; Sun, Wanling ; Cao, Yaofang ; Hui, Wuhan ; Tan, Shuai

BACKGROUND:

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm. Although Ruxolitinib, a JAK1/2 inhibitor, remains the cornerstone of MF treatment, it does not reverse disease progression, and resistance frequently emerges. These limitations have prompted investigation into combination therapies targeting pathways beyond the JAK-STAT axis. This meta-analysis aims to evaluate the efficacy and safety of Ruxolitinib-based combination therapies in patients with MF.

METHODS:

We conducted a systematic search of databases for studies published through August 1, 2025. Thirteen distinct Ruxolitinib-based combination regimens were included. Primary efficacy endpoints were ≥35% spleen volume reduction at 24 weeks (SVR35) and ≥50% reduction in total symptom score (TSS50). Safety endpoints focused on the incidence of grade 3/4 thrombocytopenia and anemia. Subgroup analyses were performed based on prior JAK inhibitor exposure and therapeutic mechanism of action.

RESULTS:

A total of 19 studies comprising 1,088 patients were included in the meta-analysis. Among JAK inhibitor-naïve patients, the combination of Ruxolitinib with Selinexor demonstrated the highest efficacy (SVR35: 92%; TSS50: 78%), followed by Ruxolitinib plus BMS-986158 (SVR35: 90%). For patients with prior JAK inhibitor exposure, Ruxolitinib plus Siremadlin (SVR35: 45%) showed notable activity.

CONCLUSION:

For JAK inhibitor-naïve patients, Ruxolitinib-based combination regimens demonstrated satisfactory clinical responses and the potential for meaningful disease control. For patients with prior JAK inhibitor exposure, the addition of combination therapy drugs may further enhance the efficacy. Personalized treatment selection remains essential, as therapeutic efficacy is significantly influenced by prior JAK inhibitor exposure.

2026-10-01·CANCER LETTERS

NPM1 mutation promotes creatine anabolism by FTO-dependent m6A demethylation to drive macrophage M2 polarization in acute myeloid leukemia

Article

作者: Long, Zi-Jie ; Lei, Xin-Xing ; Liu, Jia-Jun ; Lin, Zhi-Li ; Wang, Jun-Dan ; Liu, Quentin ; Zhang, Ling ; Peng, Zi-Zhen ; Liao, Chen-Jia

Nucleophosmin 1-mutant (NPM1^MU) acute myeloid leukemia (AML) represents a distinct molecular subtype, yet the mechanisms underlying NPM1 mutation-driven malignant transformation remain incompletely understood. Here, we find prevalent copy number variations (CNVs) of N⁶-methyladenosine (m⁶A) key regulators in NPM1 wild-type (NPM1^WT) AML patients, whereas such alterations are rarely detected in NPM1^MU subgroup. Moreover, a reduction in m⁶A modification is observed in leukemic cells overexpressing NPM1^MU protein, concomitant with an increase in FTO expression. Co-immunoprecipitation shows that NPM1^MU protein mislocates in the cytoplasm and binds to FTO to block its ubiquitin-proteasome degradation through K422 specific site. Of note, creatine metabolism-related signaling and FTO-mediated macrophage M2 polarization signaling are enriched in NPM1^MU patients according to TCGA data analysis. Indeed, FTO promotes creatine anabolism in NPM1^MU leukemic cells by stabilizing the mRNA of GAMT, a key enzyme in the creatine synthesis pathway. Creatine facilitates macrophage M2 polarization, as evidenced by the upregulation of M2 polarization-related genes (CD206, CCL2, IL-10 and CXCL13). This effect is abrogated upon FTO knockdown in leukemic cells. Selinexor, an exportin 1 inhibitor to impede NPM1^MU export from nucleus, enhances FTO degradation and reduces macrophage M2 polarization. This work reveals that FTO-creatine signaling plays an oncogenic role in NPM1^MU AML, guiding more effective therapy strategies and clinical benefits for this distinctly leukemic entity.

2026-07-01·AMERICAN JOURNAL OF HEMATOLOGY

Navigating the Post‐ BCMA / GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

Article

作者: Bartke, Leandra ; Harzer, Marie ; Brioli, Annamaria ; Khandanpour, Cyrus ; Cords, Leon ; Hillmann, Stefan M. ; Al‐Bazaz, Maximilian ; Weisel, Katja ; Holtick, Udo ; Bokemeyer, Carsten ; Artzenroth, Jule ; Kamili, Abdulaziz ; Leypoldt, Lisa ; Schaefers, Christoph ; Leitner, Theo ; Vorwerk, Jan ; Salwender, Hans ; Maulhardt, Markus ; Sonnemann, Piet ; Kosch, Ricardo ; Brinkert, Kerstin ; Richardson, Tim ; Alsdorf, Winfried

ABSTRACT:

Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies. Selinexor, an oral exportin‐1 inhibitor, offers a distinct mechanism of action and may retain efficacy in this difficult setting. We conducted a retrospective analysis at six German tertiary centers (2023–2025) to evaluate the efficacy and safety of selinexor plus bortezomib and dexamethasone (SVd) in penta‐refractory MM after both BCMA‐ and GPRC5D‐targeted therapies. Eighteen patients were identified, with a median of seven prior lines of therapy. High‐risk cytogenetic abnormalities were present in seven cases, including del17p in six. The overall response rate (ORR) was 61%, including one complete, five very good partial, and five partial responses, and median progression‐free survival (PFS) was 4.3 months. Among nine patients (50%) with extramedullary disease (EMD), three achieved complete and one near‐complete EMD resolution. Two patients who had relapsed after CAR T‐cell treatment with idecabtagene vicleucel achieved partial and very good partial responses and were successfully transitioned to a second CAR T‐cell therapy with ciltacabtagene autoleucel. Hematologic toxicities under SVd were manageable, and no treatment‐related deaths occurred. SVd demonstrates meaningful activity in patients with penta‐refractory MM and prior failure of BCMA/GPRC5D‐targeted immunotherapies. The ORR of 61%, disease control in 78% of patients, and median PFS of 4.3 months support further evaluation of SVd in this highly refractory setting after failure of BCMA‐ and GPRC5D‐directed approaches.

877

项与塞利尼索相关的新闻（医药）

2026-07-01

·PRNewswire

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,649 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of June 30, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. About Karyopharm Therapeutics Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit and follow Karyopharm on LinkedIn and on X at @Karyopharm. XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. SOURCE Karyopharm Therapeutics Inc. 21% more press release views with Request a Demo

上市批准快速通道

2026-07-01

·手机新浪网

必贝特涨7.22%，成交额2.54亿元，近3日主力净流入-488.48万

7月1日，必贝特涨7.22%，成交额2.54亿元，换手率14.15%，总市值154.32亿元。异动分析细胞免疫治疗+减肥药+创新药+科创次新股+注册制次新股1、根据招股说明书：截至本招股说明书签署日，国内已获批用于三线及以上治疗 r/r DLBCL 的药物为复星凯特引进的阿基仑赛注射液（Yescarta）、药明巨诺的瑞基奥仑赛注射液、罗氏制药的格菲妥单抗注射液（Columvi）、德琪医药引进的 Selinexor（塞利尼索片，XPOVIO，一种核输出抑制剂）、ADC Therapeutics 和瓴路药业联合申报的注射用替朗妥昔单抗、必贝特的BEBT-908（注射用盐酸伊吡诺司他）和上海恒润达生生物的雷尼基奥仑赛注射液，阿基仑赛注射液、瑞基奥仑赛注射液和雷尼基奥仑赛注射液均为 CAR-T 疗法。2、根据招股说明书：在研产品中，BEBT-808 是公司自主研发的一种口服小分子 GLP-1R 完全激动剂，用于治疗糖尿病和肥胖症，预计将于 2025 年提交临床试验申请。BEBT-809 是First-in-Class GPR75 通路抑制剂，用于治疗肥胖症，预计将于 2025 年提交临床试验申请。BEBT-701 为全球首个治疗高脂血症合并高血压的双靶点 siRNA 药物，预计将于 2025 年提交临床试验申请。3、广州必贝特医药股份有限公司主营业务是创新药物的研发、生产和销售。主要产品是小分子双靶点抑制剂。4、广州必贝特医药股份有限公司于2025-10-28上市，公司主营业务为创新药物的研发、生产和销售。5、广州必贝特医药股份有限公司于2025-10-28日上市，主营业务为创新药物的研发、生产和销售。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入-737.66万，占比0.03%，行业排名143/158，连续2日被主力资金减仓；所属行业主力净流入20.98亿，当前无连续增减仓现象，主力趋势不明显。区间今日近3日近5日近10日近20日主力净流入-737.66万-488.48万-2068.42万-2894.37万-5321.39万主力持仓主力没有控盘，筹码分布非常分散，主力成交额2867.98万，占总成交额的4.64%。技术面：筹码平均交易成本为32.14元该股筹码平均交易成本为32.14元，近期该股获筹码青睐，且集中度渐增；目前股价靠近支撑位34.20，注意支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。公司简介资料显示，广州必贝特医药股份有限公司位于广东省广州市高新技术产业开发区科学城崖鹰石路25号A-3栋第七层、第八层，成立日期2012年1月19日，上市日期2025年10月28日，公司主营业务涉及创新药自主研发。必贝特所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：小盘价值、生物医药、减肥药、抗癌药物、抗癌治癌等。截至6月18日，必贝特股东户数1.06万，较上期减少1.83%；人均流通股5025股，较上期增加1.86%。2026年1月-3月，必贝特实现营业收入0.00元；归母净利润-5273.57万元，同比减少45.49%。机构持仓方面，截止2026年3月31日，必贝特十大流通股东中，易方达医疗保健行业混合A（110023）位居第一大流通股东，持股212.76万股，相比上期增加141.99万股。博时天颐债券A（050023）位居第三大流通股东，持股112.42万股，为新进股东。长城消费增值混合A（200006）位居第七大流通股东，持股80.42万股，为新进股东。华宝生态中国混合A（000612）位居第八大流通股东，持股44.47万股，为新进股东。大摩健康产业混合A（002708）位居第九大流通股东，持股37.77万股，为新进股东。东方红医疗升级股票发起A（015052）、广发创新医疗两年持有期混合A（010731）、招商医药健康产业股票（000960）、交银医药创新股票A（004075）、广发沪港深医药混合A（014114）、东方红医疗创新混合(QDII)A（025070）、广发睿智两年持有期混合发起式A（013616）、招商前沿医疗保健股票A（011373）、融通中国风1号灵活配置混合A/B（001852）退出十大流通股东之列。

2026-06-30

·手机新浪网

必贝特涨2.80%，成交额1.58亿元，近3日主力净流入-995.12万

6月30日，必贝特涨2.80%，成交额1.58亿元，换手率9.51%，总市值143.92亿元。异动分析细胞免疫治疗+减肥药+创新药+科创次新股+注册制次新股1、根据招股说明书：截至本招股说明书签署日，国内已获批用于三线及以上治疗 r/r DLBCL 的药物为复星凯特引进的阿基仑赛注射液（Yescarta）、药明巨诺的瑞基奥仑赛注射液、罗氏制药的格菲妥单抗注射液（Columvi）、德琪医药引进的 Selinexor（塞利尼索片，XPOVIO，一种核输出抑制剂）、ADC Therapeutics 和瓴路药业联合申报的注射用替朗妥昔单抗、必贝特的BEBT-908（注射用盐酸伊吡诺司他）和上海恒润达生生物的雷尼基奥仑赛注射液，阿基仑赛注射液、瑞基奥仑赛注射液和雷尼基奥仑赛注射液均为 CAR-T 疗法。2、根据招股说明书：在研产品中，BEBT-808 是公司自主研发的一种口服小分子 GLP-1R 完全激动剂，用于治疗糖尿病和肥胖症，预计将于 2025 年提交临床试验申请。BEBT-809 是First-in-Class GPR75 通路抑制剂，用于治疗肥胖症，预计将于 2025 年提交临床试验申请。BEBT-701 为全球首个治疗高脂血症合并高血压的双靶点 siRNA 药物，预计将于 2025 年提交临床试验申请。3、广州必贝特医药股份有限公司主营业务是创新药物的研发、生产和销售。主要产品是小分子双靶点抑制剂。4、广州必贝特医药股份有限公司于2025-10-28上市，公司主营业务为创新药物的研发、生产和销售。5、广州必贝特医药股份有限公司于2025-10-28日上市，主营业务为创新药物的研发、生产和销售。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入-134.45万，占比0.01%，行业排名69/158，该股当前无连续增减仓现象，主力趋势不明显；所属行业主力净流入-15.44亿，当前无连续增减仓现象，主力趋势不明显。区间今日近3日近5日近10日近20日主力净流入-134.45万-995.12万-1840.39万-2100.65万-3979.84万主力持仓主力没有控盘，筹码分布非常分散，主力成交额3663.85万，占总成交额的6.34%。技术面：筹码平均交易成本为31.92元该股筹码平均交易成本为31.92元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近压力位32.26，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。公司简介资料显示，广州必贝特医药股份有限公司位于广东省广州市高新技术产业开发区科学城崖鹰石路25号A-3栋第七层、第八层，成立日期2012年1月19日，上市日期2025年10月28日，公司主营业务涉及创新药自主研发。必贝特所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：小盘价值、生物医药、减肥药、抗癌药物、抗癌治癌等。截至6月18日，必贝特股东户数1.06万，较上期减少1.83%；人均流通股5025股，较上期增加1.86%。2026年1月-3月，必贝特实现营业收入0.00元；归母净利润-5273.57万元，同比减少45.49%。机构持仓方面，截止2026年3月31日，必贝特十大流通股东中，易方达医疗保健行业混合A（110023）位居第一大流通股东，持股212.76万股，相比上期增加141.99万股。博时天颐债券A（050023）位居第三大流通股东，持股112.42万股，为新进股东。长城消费增值混合A（200006）位居第七大流通股东，持股80.42万股，为新进股东。华宝生态中国混合A（000612）位居第八大流通股东，持股44.47万股，为新进股东。大摩健康产业混合A（002708）位居第九大流通股东，持股37.77万股，为新进股东。东方红医疗升级股票发起A（015052）、广发创新医疗两年持有期混合A（010731）、招商医药健康产业股票（000960）、交银医药创新股票A（004075）、广发沪港深医药混合A（014114）、东方红医疗创新混合(QDII)A（025070）、广发睿智两年持有期混合发起式A（013616）、招商前沿医疗保健股票A（011373）、融通中国风1号灵活配置混合A/B（001852）退出十大流通股东之列。

100 项与塞利尼索相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11222	塞利尼索	L01XX66	DB11942

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
滤泡性淋巴瘤	印尼	德琪医药有限公司	2025-03-05
难治性多发性骨髓瘤	中国	Karyopharm Therapeutics, Inc.	2021-12-14
复发性多发性骨髓瘤	中国	Karyopharm Therapeutics, Inc.	2021-12-14
复发性弥漫性大B细胞淋巴瘤	以色列	Karyopharm Therapeutics, Inc.	2021-02-04
难治性弥漫性大 B 细胞淋巴瘤	以色列	Karyopharm Therapeutics, Inc.	2021-02-04
弥漫性大B细胞淋巴瘤	美国	Karyopharm Therapeutics, Inc.	2020-06-22
多发性骨髓瘤	美国	Karyopharm Therapeutics, Inc.	2019-07-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性急性髓细胞白血病	临床3期	中国	德琪医药有限公司	2023-01-29
复发性急性髓细胞白血病	临床3期	中国	德琪医药有限公司	2023-01-29
子宫内膜癌	临床3期	中国	Karyopharm Therapeutics, Inc.	2021-10-27
子宫内膜癌	临床3期	中国	德琪医药有限公司	2021-10-27
真性红细胞增多症后骨髓纤维化	临床3期	美国	Karyopharm Therapeutics, Inc.	2021-03-11
真性红细胞增多症后骨髓纤维化	临床3期	澳大利亚	Karyopharm Therapeutics, Inc.	2021-03-11
真性红细胞增多症后骨髓纤维化	临床3期	比利时	Karyopharm Therapeutics, Inc.	2021-03-11
真性红细胞增多症后骨髓纤维化	临床3期	保加利亚	Karyopharm Therapeutics, Inc.	2021-03-11
真性红细胞增多症后骨髓纤维化	临床3期	加拿大	Karyopharm Therapeutics, Inc.	2021-03-11
真性红细胞增多症后骨髓纤维化	临床3期	捷克	Karyopharm Therapeutics, Inc.	2021-03-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04562389 (SENTRY, EHA2026)	临床3期	骨髓纤维化	353	Selinexor+Ruxolitinib	範衊衊襯鹽網遞鬱膚繭(壓選醖餘窪願窪襯窪鹹) = 製醖網簾艱齋餘糧積醖廠糧築簾簾夢壓廠觸網 (選選繭範鬱鬱鹹夢憲艱 ) 更多	积极	2026-06-02
NCT04562389 (SENTRY, EHA2026)	临床3期	骨髓纤维化	353	Placebo+Ruxolitinib	範衊衊襯鹽網遞鬱膚繭(壓選醖餘窪願窪襯窪鹹) = 繭齋餘餘鹽衊餘範選鏇廠糧築簾簾夢壓廠觸網 (選選繭範鬱鬱鹹夢憲艱 ) 更多	积极	2026-06-02
NCT02835222 (ASCO2026)	临床2期	急性髓性白血病	57	Selinexor + standard intensive induction and consolidation chemotherapy	積鬱鏇範鏇衊鑰繭餘壓(糧糧製願糧鏇遞襯衊鑰) = 淵憲範鹹觸餘構膚齋選鹹襯簾鹹鑰蓋襯觸淵築 (艱艱獵淵鹹繭網構艱鹹 ) 更多	积极	2026-05-29
NCT02835222 (ASCO2026)	临床2期	急性髓性白血病	57	Standard intensive induction and consolidation chemotherapy	積鬱鏇範鏇衊鑰繭餘壓(糧糧製願糧鏇遞襯衊鑰) = 壓顧獵廠齋餘襯繭壓選鹹襯簾鹹鑰蓋襯觸淵築 (艱艱獵淵鹹繭網構艱鹹 ) 更多	积极	2026-05-29
EHA2026	临床1期	高危骨髓增生异常综合征	6	Standard regimen: Azacitidine 75 mg/m² D1-7 + Selinexor 60 mg D1,8,15 (28-day cycle)	鬱鹽觸壓構襯衊構選鹽(鹹衊壓餘齋築願廠憲鹹) = 顧顧廠願淵願鹽構觸繭淵襯繭遞顧鹽襯齋築糧 (鑰憲餘窪繭壓鑰鏇範齋 )	积极	2026-05-12
NCT05422066 (EHA2026)	临床2期	弥漫性大B细胞淋巴瘤一线	45	Selinexor in combination with the R-CHOP regimen	鑰顧觸餘簾衊憲顧築夢(衊鏇遞齋蓋鹹夢醖積鏇) = 蓋鹹範壓鑰廠築構鬱淵窪簾襯餘鏇築艱窪獵遞 (範網願鹹範壓夢獵淵選, 63.9 ~ 100) 更多	积极	2026-05-12
EUCTR2021-006229-23-IT (EHA2026)	临床2期	外周T细胞淋巴瘤	30	Selinexor+Ifosfamide+Etoposide+Dexamethasone	顧餘繭蓋窪壓壓淵繭鹽(構構艱齋繭衊夢膚觸製) = 衊網顧夢獵觸艱壓壓夢遞窪鹹顧夢構醖遞鹹鹹 (願壓壓築鹹簾淵鏇觸顧 ) 更多	不佳	2026-05-12
NCT05422027 (EHA2026)	临床1/2期	多发性骨髓瘤一线	30	Bortezomib 1.3mg/m²Lenalidomide 25mgSelinexor 60 mg qw + Bortezomib 1.3mg/m²Lenalidomide 25mgSelinexor 60 mg qw² + Bortezomib 1.3mg/m²Lenalidomide 25mgSelinexor 60 mg qw + Bortezomib 1.3mg/m²Lenalidomide 25mgSelinexor 60 mg qw0mg	鏇壓觸壓夢窪襯獵簾廠(蓋襯鬱製觸壓廠鏇積鑰) = 鹹鏇觸鏇鑰夢壓膚糧鑰艱壓製廠積鹹餘衊簾鏇 (繭醖壓網繭窪網繭淵選 ) 更多	积极	2026-05-12
ChiCTR2300069941 (EHA2026)	临床1期	AiD相关的弥漫性大B细胞淋巴瘤一线	10	Selinexor plus R-EPOCH (HIV-associated DLBCL)	築衊夢襯觸選蓋蓋顧壓(簾艱襯鬱膚鏇窪衊選衊) = 淵廠簾壓齋築蓋鑰糧憲齋遞積選壓繭觸廠顧窪 (構夢廠築願願糧遞淵網 ) 更多	积极	2026-05-12
EHA2026	N/A	急性髓性白血病 \| 难治性急性髓细胞白血病	45	XAB regimen	鏇衊膚衊簾觸壓網顧網(衊網構鹽醖鏇廠網醖鏇) = 遞鑰憲顧鑰積選蓋範膚餘蓋糧願鬱積遞窪觸憲 (鑰襯衊簾醖選膚範淵衊 ) 更多	积极	2026-05-12
EHA2026	N/A	急性髓性白血病 \| 难治性急性髓细胞白血病	45	XAB regimen (newly diagnosed (ND) AML)	鏇衊膚衊簾觸壓網顧網(衊網構鹽醖鏇廠網醖鏇) = 鹹製淵餘繭夢醖淵醖廠餘蓋糧願鬱積遞窪觸憲 (鑰襯衊簾醖選膚範淵衊 ) 更多	积极	2026-05-12
NCT05577364 (XPLORE, EHA2026)	临床1/2期	弥漫性大B细胞淋巴瘤一线 EBV-DNA	27	Selinexor + R-CHOP	鑰艱願餘築鹽憲積壓網(壓獵築築鑰齋鑰壓醖壓) = 網糧鑰獵選範鏇蓋鏇築窪壓繭顧築鬱遞鹽淵獵 (鏇範選構簾憲窪蓋蓋鏇 ) 更多	积极	2026-05-12
NORM (EHA2026)	临床2期	多发性骨髓瘤	37	Selinexor, Pomalidomide, and Dexamethasone (SPd) (Extramedullary Myeloma (EMD))	窪蓋簾觸構鏇艱願醖積(壓願鏇衊餘觸衊鏇齋壓) = haematological; neutropenia (53.3%), thrombocytopenia (40%), anaemia (36.7%). Grade 3/4 infections were reported in 16.7%. 蓋襯顧簾獵艱顧壓憲簾 (窪網窪製鏇鏇範鹽餘膚 ) 更多	积极	2026-05-12